6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

1414 trials found

diseases per page:

Showing 1 to 10 of 1,414 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05094011 (ClinicalTrials.gov)	March 1, 2023	20/7/2021	Evaluating Safety, Tolerability, and Efficacy of Autologous MitoCell Transplantation in Subjects Wit ...	A Phase I Open-Label Dose-Escalation Study toEvaluate the Safety, Tolerability, and Efficacy of Auto ...	Idiopathic Parkinson's Disease	Biological: Aadipose-Derived Mesenchymal Stem Cells	Taiwan Mitochondrion Applied Technology Co., Ltd.	NULL	Not yet recruiting	45 Years	70 Years	All	9	Phase 1	NULL
2	NCT05766813 (ClinicalTrials.gov)	March 2023	24/2/2023	Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due toParkins ...	A Randomized, Double-blind, Placebo-controlled Multicenter Study toAssess the Efficacy and Safety of ...	Parkinson Disease	Drug: Lenrispodun;Drug: Placebo	Intra-Cellular Therapies, Inc.	NULL	Recruiting	40 Years	80 Years	All	132	Phase 2	United States
3	NCT05611372 (ClinicalTrials.gov)	January 1, 2023	6/11/2022	Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease	Efficacy and Safety of Rasagiline in Prodromal Parkinson's Disease	REM Sleep Behavior Disorder;Parkinson Disease;Synucleinopathies	Drug: Rasagiline	Second Affiliated Hospital, School of Medicine, Zhejiang University	Beijing Tiantan Hospital;Xinhua Hospital, Shanghai Jiao Tong University School of Medicine;Jiangsu P ...	Not yet recruiting	30 Years	75 Years	All	732	Phase 2/Phase 3	NULL
4	NCT05610189 (ClinicalTrials.gov)	December 15, 2022	2/11/2022	Multiple-dose Trial toDetermine the Clinical Bioequivalence Between Tavapadon Tablets in Participant ...	A Phase 1, Randomized, Multiple-dose, Crossover Trial in Participants With Parkinson's Disease toEva ...	Parkinson Disease	Drug: Tavapadon	Cerevel Therapeutics, LLC	NULL	Recruiting	45 Years	80 Years	All	24	Phase 1	United States
5	EUCTR2021-004849-20-AT (EUCTR)	13/12/2022	05/08/2022	A Study toAssess the Safety of BIIB122 Tablets and if it can Slow the Worsening of Early-Stage Parki ...	A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study toDetermine the Efficacy ...	Parkinson's Disease MedDRA version: 20.0;Level: PT;Classification code 10061536;Term: Parkinson's di ...	Product Name: BIIB122 Product Code: DNL151, DN0001575, DN1575 INN or Proposed INN: NA Other descriptive ...	Biogen Idec Research Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	640	Phase 2	United States;Spain;Austria;Israel;Italy;United Kingdom;France;Canada;Poland;Netherlands;Germany;Chi ...
6	NCT05642442 (ClinicalTrials.gov)	December 1, 2022	30/11/2022	A Study of Suvecaltamide in Adults With Moderate to Severe Residual Tremor in Parkinson's Disease	A 17-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Flexible-dosing, Parallel-group, M ...	Parkinson Disease;Tremor	Drug: Placebo;Drug: Suvecaltamide	Jazz Pharmaceuticals	NULL	Recruiting	40 Years	80 Years	All	160	Phase 2	United States
7	NCT05635409 (ClinicalTrials.gov)	November 30, 2022	15/11/2021	A Trial toDetermine the Safety and Tolerability of Transplanted Stem Cell Derived Dopamine Neurons t ...	STEM-PD Trial: A Multicentre, Single Arm, First in Human, Dose-escalation Trial, Investigating the S ...	Parkinson Disease	Biological: STEM-PD	Region Skane	Lund University;Cambridge University Hospitals NHS Foundation Trust;University of Cambridge	Recruiting	50 Years	75 Years	All	8	Phase 1	Sweden;United Kingdom
8	NCT05581823 (ClinicalTrials.gov)	October 19, 2022	12/10/2022	Study toEvaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmac ...	A Phase 1, Open-label, Fixed-sequence, Crossover Trial toEvaluate the Effects of Cytochrome P450 (CY ...	Parkinson Disease	Drug: Tavapadon;Drug: Carbamazepine	Cerevel Therapeutics, LLC	NULL	Active, not recruiting	18 Years	55 Years	All	16	Phase 1	United States
9	NCT05635461 (ClinicalTrials.gov)	October 9, 2022	7/11/2022	Relative Bioavailability and Food Effect Study of CVN424	A Randomized, Open-Label, Single Oral Dose, Three-Way Cross-Over Trial toEvaluate the Relative Bioav ...	Parkinson Disease	Drug: CVN424	Cerevance Beta, Inc.	NULL	Completed	18 Years	55 Years	All	32	Phase 1	United States
10	NCT05603312 (ClinicalTrials.gov)	October 5, 2022	12/10/2022	A Double-blind Study toEvaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson ...	A Randomized, Double-Blind, Sham-Controlled Study toEvaluate the Safety and Tolerability of Glutamic ...	Parkinson Disease	Genetic: AAV-GAD Dose 1;Genetic: AAV-GAD Dose 2;Procedure: Sham Surgery	MeiraGTx, LLC	NULL	Recruiting	25 Years	85 Years	All	14	Phase 1/Phase 2	United States

First Previous1 2 3 4 5…142Next Last